サイネオス・ヘルスが、バイオ後続品開発のパートナーとして選ばれる理由

The biosimilar market is evolving rapidly, with an ever-changing regulatory landscape and new market entrants in both emerging and developed markets. Since the first biosimilar regulatory framework was introduced by EMA in 2003 (followed by U.S. in 2009, WHO in 2010 and India in 2016) the industry has matured.

Click here to read our biosimilars fact sheet